Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in chronic inducible urticaria inadequately controlled by H1-antihistamines
jRCT2061230109Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in chronic inducible urticaria (CIndU), symptomatic dermatographism (SD), Cold urticaria (CU) and 1 more comparing Remibrutinib with Placebo/Remibrutinib OLE (2 arms). Primary endpoints: Proportion of participants with complete response in Total Fric Score (symptomatic dermographism) at Week 12, Proportion of participants with complete response in critical temperature threshold (cold urticaria) at Week 12 and 1 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic inducible urticaria (CIndU)symptomatic dermatographism (SD)Cold urticaria (CU)Cholinergic Urticaria (CU)
Beyond the preview
Go deeper on jRCT2061230109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230109.